Medicinova (MNOV) Announces Positive Findings on MN-001 in Acute Liver Injury Model to be Presented at The Liver Meeting

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive findings from a study evaluating MN-001 (tipelukast) in an acute liver injury model will be presented at The Liver Meeting Digital Experience™ 2020 (TLMdX™), an event of the American Association for the Study of Liver Diseases (AASLD). The study is the results of a collaborative effort between MediciNova and Dr. Craig McClain and Dr. Leila Gobejishvili at the University of Lousiville School of Medicine.

The poster presentation entitled "MODULATION OF TGFβ1 SIGNALING BY INTERACTION OF cAMP EFFECTORS AND TGFβ1 TYPE I RECEPTOR IN HEPATIC STELLATE CELLS" is authored by principal researcher, Dr. Leila Gobejishvili, Associate Professor, University of Louisville School of Medicine, Division of Gastroenterology, Hepatology and Nutrition.

Due to the COVID-19 pandemic, TLMdX™ will be held November 13-16, 2020 in its digital format. The poster session will be open and available during the entirety of TLMdX™ 2020.

Presentation details are as follows:

Publication Number: 0317

Session Title: Basic Fibrosis Research and Stellate Cell Biology

Presentation Type: Poster Presentation

Dates: November 13-16, 2020

You May Also Be Interested In

• Hepion Pharmaceuticals (HEPA) Winds Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
• Ocular Therapeutix (OCUL) Reports Positive Topline Phase 1 Data for AXPAXLI
• Inhibikase Therapeutics (IKT) Issues Letter to Shareholders and Provides Update on Development Programs